Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Inhaled Aclidinium Bromide in Healthy Chinese Participants
NCT03276052Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2021
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of aclidinium in chronic obstructive pulmonary disease (COPD), sponsored by AstraZeneca. Primary endpoints: Maximum Observed Plasma Concentration at Day 9, Time to Reach Maximum Observed Concentration at Day 9 and 11 more. Started Oct 2021; status: completed.
02
Drugs
aclidinium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03276052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03276052.